Objectives HIV‐1 transmitted drug resistance (TDR) in treatment‐naïve individuals is a well‐
described phenomenon. Baseline genotypic resistance testing is considered standard of …

With 29 individual antiretroviral drugs available from six classes that are approved for the
treatment of HIV-1 infection, a combination of different phenotypic and genotypic tests is …

Reports of a high frequency of the transmission of minority viral populations with drug-
resistant mutations (DRM) are inconsistent with evidence that HIV-1 infections usually arise …

Technologic advances in human immunodeficiency virus type 1 (HIV-1) sequencing have
revolutionized the study of antiretroviral drug resistance and are increasingly moving from …

Objectives: K103N, the most common nonnucleoside reverse transcriptase inhibitor (NNRTI)-
resistant mutation in patients with transmitted resistance and in patients receiving a failing …

Limited access to HIV drug resistance testing in low-and middle-income countries impedes
clinical decision-making at the individual patient level. An efficient protocol to address this …

Human immunodeficiency virus type-1 (HIV-1) exhibits high between-host genetic diversity
and within-host heterogeneity, recognized as quasispecies. Because HIV-1 quasispecies …

HIV drug resistance is a major global challenge to successful and sustainable antiretroviral
therapy. Next-generation sequencing (NGS)-based HIV drug resistance (HIVDR) assays …

Conventional HIV drug resistance (HIVDR) genotyping utilizes Sanger sequencing (SS)
methods, which are limited by low data throughput and the inability of detecting low …

The emerging HIV-1 resistance epidemic is threatening the impressive global advances in
HIV-1 infection treatment and prevention achieved in the last decade. Next-generation …